Jump to main navigation | Jump to sub navigation | Jump to SiteMap | Jump to Home Page |
| Oncology |
| Inflammatory Bowel Disease |
| Oncology Supportive Care (Mucositis) |
| Dermatology |
| Histology and Molecular Services |
| Scientific Overview |
| Discovery Platform |
| Emerging Protein Therapeutic Pipeline |
| Partnerships |
| Biomarkers |
| Genedrive |
| Epistem PLC |
| Epistem Inc |
| Investor Information |
| Company Profile |
| Shareholder Information |
| Share Price Information |
| RNS Announcements |
| Directors |
| Company Reports |
| Constitutional Documents |
| Corporate Governance |
| Advisors |
| Press Releases |
| Events |
| How to find us |
Oncology
Epistem's preclinical oncology platform is an integrated offering, combining a comprehensive range of assays with a high level of oncology expertise. Epistem has a track record of delivering high quality preclinical data to our pharmaceutical clients, many of which have progressed towards the clinical phases.
Epistem's preclinical oncology platform includes: